Clinical Trials

90 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT05951179 2026-05-18

ADVANCED-2

131 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT05316155 2026-05-08

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

235 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06319820 2026-05-08

MoonRISe-1

Phase 3 Recruiting

641 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06919965 2026-05-08

MoonRISe-3

Phase 3 Recruiting

220 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07309445 2026-05-08

Nova-sTAR

Recruiting

150 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06637423 2026-05-01

TroFuse-027

32 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04752722 2026-04-30

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

350 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT07283835 2026-04-23

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

16 enrolled

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT07206225 2026-04-21

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

Phase 1 Recruiting

294 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05483868 2026-04-15

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Phase 1 Recruiting

55 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06833073 2026-04-06

INTerpath-011

308 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT07144319 2026-04-01

ENAiBLE

Recruiting

500 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06800963 2026-03-27

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

40 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT02660645 2025-12-18

BLCCR

Recruiting

4,400 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03945162 2025-11-24

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

90 enrolled

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07122414 2025-08-14

A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer

80 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06663137 2025-06-13

HGNMIBC

70 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06186414 2025-01-15

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC

Phase 1 Recruiting

152 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT05232136 2024-08-12

OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer

30 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06241755 2024-02-05

Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 3 Recruiting

412 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05943379 2023-07-13

RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects

85 enrolled